Loading…
← CockpitCompetitor Analysis › 603367.SS Cisen Pharmaceutical Ltd. Class AOpen in the cockpit ↗

Cisen Pharmaceutical Ltd. Class A603367.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties
Momentum strong 61
Mkt cap
$843M
US dollars, full cap
Free float
43%
of shares outstanding
$/day
$8.73M
20-day average traded
Fwd P/E
7.9×
forward earnings
ROIC−WACC
+3.9 pp
WACC 6.0%
Hurdle
-13 pp
Req g minus delivered
Close · CNYCN¥12.65
1D-0.3%
1W-3.8%
1M-8.9%
3M-17.1%
6M-14.6%
YTD-27.0%
1Y-39.6%
ATR %2.3%
52w lowhigh42.5% off high

What Cisen Pharmaceutical does

Employees: 3,114

Cisen Pharmaceutical at a glance

Size Cisen Pharmaceutical (603367.SS) is a China Health Care company (Medical Specialties) with a market value of $843M, the 2489th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.65 on 18 Nov 2026.

Performance Over six months the shares fell 14.6%, against -14.0% for the median peer and -20.0% for the China market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 6.4% over the last twelve months (peer median +10.4%); the operating margin is 8.2% (peer median 10.0%).

Valuation It trades at 7.9× forward earnings against a peer median of 26.0× (cheapest of 15).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -13 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.9 points above its cost of capital (6.0% WACC).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026Peer median 86603367.SS 86
Six months, rebased to 100: Cisen Pharmaceutical against the median of its 20 peers (local-currency closes).

Cisen Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.34BCN¥3.42BCN¥3.95BCN¥4.42BCN¥4.03B
Revenue growth—-14%-11%+10%—
Gross profitCN¥1.83BCN¥1.66BCN¥2.09BCN¥2.46BCN¥2.14B
EBITDAn/aCN¥458MCN¥639MCN¥749MCN¥522M
Net incomeCN¥387MCN¥421MCN¥509MCN¥521MCN¥350M
Free cash flowCN¥578MCN¥555MCN¥533MCN¥480MCN¥259M
Capital expenditureCN¥8.59MCN¥64.8MCN¥102MCN¥17.7MCN¥35.2M
Total debtCN¥252MCN¥399MCN¥576MCN¥529MCN¥478M

Quarterly statements and history in the cockpit →

Cisen Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%36001187301602688656KIDS002658688805688277688068MCAPAMS688626688767096530688575301580BVSAORTSETL603367.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Cisen Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×36001187688656002658MCAPAMS688626688767096530688575BVSAORTKURN603367.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Cisen Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%36001187301602688656002658688805MCAPAMS096530688575301580BVS603367.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Cisen Pharmaceutical is the large dot.

Cisen Pharmaceutical competitors and peer comparison

How Cisen Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Cisen Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure603367.SSPeer medianRank in peer set
1-month return-8.9%-6.4%8th lowest of 21
6-month return-14.6%-14.0%11th highest of 21
Distance from 52-week high-42.5%-41.1%10th lowest of 21
Revenue growth (TTM)-6.4%+10.4%2nd lowest of 21
Operating margin8.2%10.0%9th lowest of 21
Forward P/E7.9×26.0×cheapest of 15
Growth the price implies (Req g, 7 yrs)-14.6%9.3%least demanding of 13
Growth delivered (Del g)-1.3%+12.2%2nd lowest of 13
Hurdle (Req g minus delivered)-13.3 pp-2.7 pp3rd least demanding of 13
ROIC minus cost of capital+3.9 pp+1.5 pp7th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a

Questions

Which companies are Cisen Pharmaceutical's closest peers?
The cockpit's peer set: Modern Dental (3600.HK), Cofoe Medical Technology (1187.HK), Shantou Institute of Ultrasonic Instruments (301602.SZ), HOB Biotech (688656.SS), OrthoPediatrics (KIDS), Beijing SDL Technology (002658.SZ), Ningbo Jansen Superconducting Technologies (688805.SS), Tinavi Medical Technologies (688277.SS).
Is Cisen Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 7.9× against a peer median of 26.0×, cheapest of 15 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -13 pp: the price already allows for a slowdown.
How has Cisen Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -14.6% against -14.0% for the median peer; over one year -39.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.